HIV-1 integrase inhibitors: 2007โ2008 up
โ
Kavya Ramkumar; Erik Serrao; Srinivas Odde; Nouri Neamati
๐
Article
๐
2010
๐
John Wiley and Sons
๐
English
โ 892 KB
In recent years, HIV-1 integrase (IN) has become an attractive target for designing antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated the pharmacological viability of IN inhibitors and signals the advent of a new generation of antiretroviral drugs. T